AveXis
Bannockburn, US · Founded 2012 · 4 known investors
New gene therapy treatments for people with serious, rare diseases. (NASDAQ: BOLD) (Acquired by Astellas)
Founders & leadership
JL
James L'ItalienNamed on SEC filing
AF
Andrew F. KnudtenNamed on SEC filing
PM
Paul ManningNamed on SEC filing
SN
Sukumar NagendranNamed on SEC filing
BK
Bong KohNamed on SEC filing
TD
Thomas DeeNamed on SEC filing
SN
Sean NolanNamed on SEC filing
CN
Carole NuechterlainNamed on SEC filing
BK
Brian KasparNamed on SEC filing
JD
John D. HarkeyNamed on SEC filing
Board
JL
Jonathan LeffBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$65M disclosed across 1 round · 2015
▶$65MraisedSep 2015 · 27 investors · BiotechnologyRule 506(b)
▶$65MraisedSep 2015 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James L'ItalienExecutive Officer
- Andrew F. KnudtenExecutive Officer
- Paul ManningDirector
- Sukumar NagendranExecutive Officer
- Bong KohDirector
- Thomas DeeExecutive Officer
- Sean NolanExecutive Officer, Director
- Carole NuechterlainDirector
- Brian KasparExecutive Officer, Director
- Jonathan LeffDirector
- John D. HarkeyDirector
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does AveXis do?
- New gene therapy treatments for people with serious, rare diseases. (NASDAQ: BOLD) (Acquired by Astellas)
- Who are AveXis's investors?
- AveXis's investors include Foresite Capital, PBM Capital, RA Capital, Sofinnova Ventures.
- How much funding has AveXis raised?
- AveXis has disclosed $65M raised across 1 round.
- Where is AveXis headquartered?
- AveXis is headquartered in Bannockburn, US.